Particulars (Rupees in Crores.) | Jun-2025 | Mar-2025 | Dec-2024 | Sept-2024 | Jun-2024 |
---|---|---|---|---|---|
Gross Sales | 130.3 | 104.87 | 103.02 | 90.59 | 79.5 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 130.3 | 104.87 | 103.02 | 90.59 | 79.5 |
Other Operating Income | 7.69 | 9.34 | 0 | 10.04 | 0.89 |
Other Income | 3.36 | 11.77 | 5.16 | 1.85 | 0.48 |
Total Income | 141.35 | 125.98 | 108.18 | 102.48 | 80.87 |
Total Expenditure | 103.83 | 94.77 | 77.33 | 77.38 | 59.07 |
PBIDT | 37.52 | 31.21 | 30.85 | 25.1 | 21.8 |
Interest | 5.04 | 5.3 | 6.16 | 5.27 | 4.82 |
PBDT | 32.48 | 25.91 | 24.69 | 19.83 | 16.98 |
Depreciation | 5.99 | 5.23 | 4.2 | 3.89 | 3.52 |
Minority Interest Before NP | 0 | 0 | 0 | 0 | 0 |
Tax | 4.91 | 6.73 | 6.1 | 1.41 | 1.32 |
Deferred Tax | 0.4 | -4.02 | -2.04 | 1.5 | 1.23 |
Reported Profit After Tax | 21.18 | 17.97 | 16.43 | 13.03 | 10.91 |
Minority Interest After NP | 1.45 | 0.14 | -0.75 | 0.21 | 0.18 |
Net Profit after Minority Interest | 19.73 | 17.83 | 17.18 | 12.82 | 10.73 |
Extra-ordinary Items | 0 | 0 | 0 | 0 | 0 |
Adjusted Profit After Extra-ordinary item | 19.73 | 17.83 | 17.18 | 12.82 | 10.73 |
EPS (Unit Curr.) | 4.6 | 3.81 | 5.04 | 2.78 | 3.39 |
Book Value (Unit Curr.) | 0 | 0 | 0 | 0 | 0 |
Dividend (%) | 0 | 0 | 0 | 0 | 0 |
Equity | 46.05 | 46.05 | 46.05 | 46.05 | 33.27 |
Public Shareholding (Number) | 0 | 0 | 0 | 0 | 0 |
Public Shareholding (%) | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Pledged/Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - No. of Shares | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Promoters Holding | 0 | 0 | 0 | 0 | 0 |
Non Encumbered - % in Total Equity | 0 | 0 | 0 | 0 | 0 |
PBIDTM(%) | 28.79 | 29.76 | 29.94 | 27.7 | 27.42 |
PBDTM(%) | 24.92 | 24.7 | 23.96 | 21.88 | 21.35 |
PATM(%) | 16.25 | 17.13 | 15.94 | 14.38 | 13.72 |
Senores Pharmaceuticals intends to fund the acquisition through proceeds from its IPO, which raised ₹5.82 billion in December.
Senores Pharmaceuticals shares closed 6% below their listing price, although they are still up 43% from the IPO price.
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248, DP SEBI Reg. No. IN-DP-185-2016
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.